hydroxy-L-Proline methyl ester hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: hydroxy-L-Proline methyl ester hydrochloride
• 英文别名: L-hydroxyproline methyl ester hydrochloride；cis-hydroxy-L-proline methyl ester hydrochloride salt；hydroxy L-proline methyl ester hydro chloride；methyl (2S)-1-hydroxypyrrolidine-2-carboxylate;hydrochloride
• 化学式: C₆H₁₁NO₃*ClH
• 分子量: 181.619
• InChiKey: GKOJGKLSWYPJCM-JEDNCBNOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.43
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  hydroxy-L-Proline methyl ester hydrochloride 在 碘 、 碳酸氢钠 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 8.17h， 生成 (S)-N-(acetoxymethyl)-N-[(1R,2S,5R)-menthyloxycarbonyl]-4-(1,4,7,10-tetraoxa-13-azacyclopentadecan-13-yl)homoalanine methyl ester
  参考文献：
  名称：

  EP2957555

  摘要：

  公开号：

文献信息

• [EN] PYRROLIDINE DERIVATIVES AS OXYTOCIN ANTAGONISTS<br/>[FR] DERIVES DE PYRROLIDINE UTILISES EN TANT QU'ANTAGONISTES DE L'OXYTOCINE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2004005249A1

  公开（公告）日：2004-01-15

  The present invention relates to novel pyrrolidine derivative of formula (I), its geometrical isomers, its optically active forms as enantiomers, diastereomers, mixtures of these and its racemate forms, as well as salts thereof, wherein R1 is selected from the group comprising or consisting of H and C1-C6-alkyl, for the prevention and/or treatment of preterm labor, premature birth or dysmenorrhea.

  本发明涉及公式（I）的新型吡咯烷衍生物，其几何异构体，其光学活性形式如对映体，非对映体，这些的混合物及其外消旋形式，以及其盐，其中R1选自包括或由H和C1-C6-烷基组成的群，用于预防和/或治疗早产、早产或痛经。
• VLA-4 INHIBITOR
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1757602A1

  公开（公告）日：2007-02-28

  An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y1 represents a divalent aryl group etc. , V1 represents an aryl group etc., and R11 to R14 represent H, OH or a halogen atom etc.]

  本发明的一个目的是提供一种化合物，该化合物选择性地抑制配体与α4β1整合素（VLA-4）的结合，以及包含该化合物的药物的制备过程。化合物的结构如公式（I）所示，或其盐，制备该化合物或其盐的过程，包含该化合物或其盐的药物，以及作为细胞粘附引起的疾病（例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻阻塞、糖尿病、关节炎、银屑病、多发性硬化症、炎症性肠病和移植排斥反应等）的预防和/或治疗剂，包含该化合物或其盐作为主要成分。【其中Y1代表双价芳基等，V1代表芳基等，R11至R14代表H、OH或卤素原子等】
• Modified oligonucleotides and compound that can be used for synthesizing same
  申请人：GUANGZHOU RIBOBIO CO., LTD.

  公开号：US20200369703A1

  公开（公告）日：2020-11-26

  The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleatides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.

  本公开涉及生物医学技术领域，特别是涉及改良寡核苷酸和一种可用于合成相同的化合物以及一种修改寡核苷酸的方法。本公开还涉及使用改良寡核苷酸来预防和/或治疗与主体肝脏相关的疾病。
• THERAPEUTIC ANTIVIRAL PEPTIDES
  申请人：BUCKMAN BRAD

  公开号：US20100119479A1

  公开（公告）日：2010-05-13

  Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, medicaments, and dosage forms related thereto are also disclosed.

  本文披露了由以下公式表示的化合物：同时还披露了相关的治疗方法、组合物、药物和剂型。
• 2-(2-vinylpyrrolidinylthio)carbapenem derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05095013A1

  公开（公告）日：1992-03-10

  A compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or a methyl group, R.sup.2 is a hydrogen atom or a lower alkyl group, each of R.sup.3, R.sup.4 and R.sup.5 is a hydrogen atom or a lower alkyl group, or R.sup.3 and R.sup.4 together form a methylene group, an ethylene group or a propylene group, or R.sup.4 and R.sup.5 form together with the adjacent nitrogen atom an aziridinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidino group, a piperazinyl group or a morpholino group; or a pharmaceutically acceptable salt or ester thereof.

  该化合物的化学式为：##STR1## 其中R.sup.1是氢原子或甲基基团，R.sup.2是氢原子或较低的烷基基团，R.sup.3、R.sup.4和R.sup.5中的每一个是氢原子或较低的烷基基团，或者R.sup.3和R.sup.4一起形成亚甲基基团、乙烯基团或丙烯基团，或者R.sup.4和R.sup.5与相邻的氮原子一起形成环氮丙基团、环氮乙基团、吡咯啶基团、哌啶基团、哌嗪基团或吗啉基团；或其药用可接受的盐或酯。